What's In Store For Innoviva (INVA) This Earnings Season?
Zacks Investment Research | Feb 03, 2020 10:19PM ET
We expect royalties from Innoviva, Inc.’s (NASDAQ:INVA) collaborated drugs to have driven revenues in fourth-quarter 2019.
Shares of the company have lost 12.4% in the past year.
Innoviva’s earnings performance has been dismal over the trailing four quarters. The company missed expectations in three of the last four quarters. The trailing four-quarter negative earnings surprise is 15.82%, on average.
In the last reported quarter, Innoviva delivered a negative earnings surprise of 10.0%.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Innoviva has a long-acting beta2 agonist (“LABA”) collaboration agreement with British pharma giant, Glaxo (NYSE:GSK) , which is the sole revenue source for the former. Under this agreement, Innoviva records royalties on global sales of certain Glaxo’s Ellipta products — Relvar/Breo, Anoro and Trelegy. Demand for these respiratory drugs is likely to have driven revenues for the company.
Trelegy Ellipta, the most recent among these, has demonstrated a strong growth trend in the first nine months of 2019. We expect strong demand for the drug to have continued in the fourth quarter, driving sales.
Moreover, U.S. sales of Anoro Ellipta returned to growth and ex-U.S. sales were strong in the third quarter. The sales-growth trend is likely to have continued in the soon-to-be reported quarter.
However, the U.S. generic launch of Glaxo’s respiratory drug, Advair, in early 2019 negatively impacted pricing for Relvar/Breo Ellipta in the United States. We expect U.S. sales to have declined in the quarter. Meanwhile, share gains in certain European markets and growth in Japan are likely to have driven sales in ex-U.S. markets for Relvar/Breo Ellipta.
We expect foreign currency translation to have positively impacted ex-U.S. sales of these drugs, thus driving royalties for Innoviva.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Innoviva this season. The combination of a positive Earnings ESP Filter .
Earnings ESP: Innoviva’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at earnings of 60 cents.
Zacks Rank: Innoviva currently carries a Zacks Rank #3.
Innoviva, Inc. Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.